Objective: To explore the levels of serum and ascitic fluid soluble tumor necrosis factor receptor-p55 (sTNFR-p55) and understand their clinical implication in primary hepatocellular carcinoma (HCC) patients. Methods:...Objective: To explore the levels of serum and ascitic fluid soluble tumor necrosis factor receptor-p55 (sTNFR-p55) and understand their clinical implication in primary hepatocellular carcinoma (HCC) patients. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to examine the levels of sTNFR-p55 in the serum and ascitic fluid in 25 HCC patients and 25 patients with liver cirrhosis (LC). The test was also performed on the serum of 30 healthy subjects who served as control group. To assess the clinical effects of increased serum concentrations of sTNFR-p55, four parameters were analyzed by logistic regression. Results: Serum and ascitic fluid levels of sTNFR-p55 in HCC patients were significantly higher than those in LC patients and controls (P=0. 001). No significant difference was found between serum sTNFR-p55 levels in the latter 2 groups (P = 0. 19), and positive correlation between serum levels of sTNFR-p55 and that in ascitic fluid was noted in the 2 patient groups (r=1. 000, P<0. 001). Levels of the sTNFR-p55 positively correlated with TBIL and AFP in the peripheral blood of HCC patients (r=0. 524, P = 0. 01 and r=0. 234, P = 0. 03, respectively). Conclusion: Increased levels of sTNFRs-p55 in the serum and ascitic fluid could reflect the abnormal immune status of the HCC patients and may help predict the development of the tumor.展开更多
目的构建重组质粒柯萨奇病毒A组16型(coxsackievirus group A type 16,CA16)VP1,并进行原核表达及鉴定。方法用PCR方法扩增CA16 VP1序列,构建其重组表达质粒pET21b-CA16 VP1,并转入大肠杆菌E.coli BL21(DE3)进行诱导表达及纯化,SDS-PAG...目的构建重组质粒柯萨奇病毒A组16型(coxsackievirus group A type 16,CA16)VP1,并进行原核表达及鉴定。方法用PCR方法扩增CA16 VP1序列,构建其重组表达质粒pET21b-CA16 VP1,并转入大肠杆菌E.coli BL21(DE3)进行诱导表达及纯化,SDS-PAGE鉴定表达及纯化产物,间接ELISA方法检测重组蛋白CA16 VP1的抗原性和有效性。结果成功原核表达并纯化了CA16 VP1蛋白,可与小鼠抗CA16病毒血清特异性结合,与太原市老年人群中部分血清存在高反应性。结论 CA16 VP1蛋白获得成功表达,ELISA检测具有良好的抗原性和有效性,为CA16诊断试剂盒的研究奠定基础。展开更多
文摘Objective: To explore the levels of serum and ascitic fluid soluble tumor necrosis factor receptor-p55 (sTNFR-p55) and understand their clinical implication in primary hepatocellular carcinoma (HCC) patients. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to examine the levels of sTNFR-p55 in the serum and ascitic fluid in 25 HCC patients and 25 patients with liver cirrhosis (LC). The test was also performed on the serum of 30 healthy subjects who served as control group. To assess the clinical effects of increased serum concentrations of sTNFR-p55, four parameters were analyzed by logistic regression. Results: Serum and ascitic fluid levels of sTNFR-p55 in HCC patients were significantly higher than those in LC patients and controls (P=0. 001). No significant difference was found between serum sTNFR-p55 levels in the latter 2 groups (P = 0. 19), and positive correlation between serum levels of sTNFR-p55 and that in ascitic fluid was noted in the 2 patient groups (r=1. 000, P<0. 001). Levels of the sTNFR-p55 positively correlated with TBIL and AFP in the peripheral blood of HCC patients (r=0. 524, P = 0. 01 and r=0. 234, P = 0. 03, respectively). Conclusion: Increased levels of sTNFRs-p55 in the serum and ascitic fluid could reflect the abnormal immune status of the HCC patients and may help predict the development of the tumor.
文摘目的构建重组质粒柯萨奇病毒A组16型(coxsackievirus group A type 16,CA16)VP1,并进行原核表达及鉴定。方法用PCR方法扩增CA16 VP1序列,构建其重组表达质粒pET21b-CA16 VP1,并转入大肠杆菌E.coli BL21(DE3)进行诱导表达及纯化,SDS-PAGE鉴定表达及纯化产物,间接ELISA方法检测重组蛋白CA16 VP1的抗原性和有效性。结果成功原核表达并纯化了CA16 VP1蛋白,可与小鼠抗CA16病毒血清特异性结合,与太原市老年人群中部分血清存在高反应性。结论 CA16 VP1蛋白获得成功表达,ELISA检测具有良好的抗原性和有效性,为CA16诊断试剂盒的研究奠定基础。
